SG10201501539SA - Treatment of lupus arthritis using laquinimod - Google Patents

Treatment of lupus arthritis using laquinimod

Info

Publication number
SG10201501539SA
SG10201501539SA SG10201501539SA SG10201501539SA SG10201501539SA SG 10201501539S A SG10201501539S A SG 10201501539SA SG 10201501539S A SG10201501539S A SG 10201501539SA SG 10201501539S A SG10201501539S A SG 10201501539SA SG 10201501539S A SG10201501539S A SG 10201501539SA
Authority
SG
Singapore
Prior art keywords
laquinimod
treatment
lupus arthritis
lupus
arthritis
Prior art date
Application number
SG10201501539SA
Inventor
Asi Haviv
Nora Tarcic
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44531530&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201501539S(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of SG10201501539SA publication Critical patent/SG10201501539SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG10201501539SA 2010-03-03 2011-03-02 Treatment of lupus arthritis using laquinimod SG10201501539SA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33935510P 2010-03-03 2010-03-03

Publications (1)

Publication Number Publication Date
SG10201501539SA true SG10201501539SA (en) 2015-04-29

Family

ID=44531530

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201501539SA SG10201501539SA (en) 2010-03-03 2011-03-02 Treatment of lupus arthritis using laquinimod
SG2012063517A SG183515A1 (en) 2010-03-03 2011-03-02 Treatment of lupus arthritis using laquinimod

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2012063517A SG183515A1 (en) 2010-03-03 2011-03-02 Treatment of lupus arthritis using laquinimod

Country Status (21)

Country Link
US (4) US20110217295A1 (en)
EP (1) EP2542080B1 (en)
JP (2) JP2013521305A (en)
KR (1) KR20130036217A (en)
CN (1) CN102781239B (en)
AU (1) AU2011223702B2 (en)
BR (1) BR112012022064A2 (en)
CA (1) CA2791711A1 (en)
CL (1) CL2012002422A1 (en)
CO (1) CO6630086A2 (en)
EA (1) EA201290859A1 (en)
ES (1) ES2601819T3 (en)
HK (1) HK1177876A1 (en)
MX (1) MX342001B (en)
NZ (1) NZ602512A (en)
PE (1) PE20130496A1 (en)
PL (1) PL2542080T3 (en)
PT (1) PT2542080T (en)
SG (2) SG10201501539SA (en)
WO (1) WO2011109536A1 (en)
ZA (1) ZA201207125B (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0617477A2 (en) * 2005-10-19 2011-07-26 Teva Pharma mixture of crystalline particles of sodium laquinimod, composition, process of crystallization of laquinimod sodium, laquinimod sodium, and process for producing a pharmaceutical composition
EP2035001B1 (en) 2006-06-12 2011-11-09 Teva Pharmaceutical Industries Limited Stable laquinimod preparations
PL2682120T3 (en) 2007-12-20 2017-02-28 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
BRPI0913518A2 (en) * 2008-09-03 2016-07-26 Teva Pharma compound, pharmaceutical composition, and method of treating an immune function mediated disorder
MX2011013902A (en) * 2009-06-19 2012-02-23 Teva Pharma Treatment of multiple sclerosis with laquinimod.
ME02414B (en) * 2009-07-30 2016-09-20 Teva Pharma Treatment of crohn's disease with laquinimod
EP3064206B1 (en) 2009-08-10 2019-03-20 Active Biotech AB Treatment of huntington's disease using laquinimod
PT2542080T (en) * 2010-03-03 2016-11-16 Teva Pharma Treatment of lupus arthritis using laquinimod
BR112012021905A2 (en) * 2010-03-03 2015-09-29 Teva Pharma treatment of lupus nephritis using laquinimod
JP5819328B2 (en) * 2010-03-03 2015-11-24 テバ ファーマシューティカル インダストリーズ リミティド Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
SG10201505236YA (en) 2010-07-09 2015-08-28 Teva Pharma Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
US8889627B2 (en) 2011-10-12 2014-11-18 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with combination of laquinimod and fingolimod
CN104093310A (en) 2012-02-03 2014-10-08 泰华制药工业有限公司 Use of laquinimod for treating crohn's disease patients who failed first-line anti-tnfalpha therapy
EP2744498A4 (en) 2012-02-16 2014-12-03 Teva Pharma N-ethyl-n-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinoline carboxamide, preparation and uses thereof
TW201350467A (en) 2012-05-08 2013-12-16 Teva Pharma N-ethyl-4-hydroxyl-1-methyl-5-(methyl(2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide
TW201400117A (en) 2012-06-05 2014-01-01 Teva Pharma Treatment of ocular inflammatory disease using laquinimod
TW201410244A (en) 2012-08-13 2014-03-16 Teva Pharma Laquinimod for treatment of GABA mediated disorders
BR112015010193A2 (en) 2012-11-07 2017-07-11 Teva Pharma laquinimod amine salts
KR20150143499A (en) 2013-03-14 2015-12-23 테바 파마슈티컬 인더스트리즈 리미티드 Crystals of laquinimod sodium and improved process for the manufacture thereof
EP2968203A1 (en) 2013-03-14 2016-01-20 Teva Pharmaceutical Industries Ltd. Transdermal formulations of laquinimod
MX2016013944A (en) 2014-04-29 2017-01-09 Teva Pharma Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status.

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2340735A1 (en) * 1976-02-11 1977-09-09 Roussel Uclaf NEW DERIVATIVES OF 3-QUINOLEINE CARBOXYLIC ACID, THEIR METHOD OF PREPARATION AND THEIR APPLICATION AS A MEDICINAL PRODUCT
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
US5540934A (en) * 1994-06-22 1996-07-30 Touitou; Elka Compositions for applying active substances to or through the skin
US5912349A (en) * 1997-01-31 1999-06-15 Pharmacia & Upjohn Company Process for the preparation of roquinimex
US6696407B1 (en) * 1997-03-21 2004-02-24 The Regents Of The University Of California Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF
SE9801474D0 (en) * 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
US6133285A (en) * 1998-07-15 2000-10-17 Active Biotech Ab Quinoline derivatives
US6121287A (en) * 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives
RS51019B (en) * 1999-10-25 2010-10-31 Active Biotech Ab. Drugs for the treatment of malignant tumours
WO2002007757A2 (en) * 2000-07-21 2002-01-31 Lue Tom F Prevention and treatment of sexual arousal disorders
US6307050B1 (en) * 2000-08-29 2001-10-23 R. T. Alamo Venture I Llc Method of synthesizing flosequinan from 4-fluoroanthranilic acid
US6875869B2 (en) * 2002-06-12 2005-04-05 Active Biotech Ab Process for the manufacture of quinoline derivatives
US7560557B2 (en) * 2002-06-12 2009-07-14 Active Biotech Ag Process for the manufacture of quinoline derivatives
US20070292461A1 (en) * 2003-08-04 2007-12-20 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US20050074451A1 (en) * 2003-06-25 2005-04-07 Elan Pharmaceuticals, Inc. Methods and compositions for treating rheumatoid arthritis
US8795693B2 (en) * 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US8314124B2 (en) * 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
SE0400235D0 (en) * 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
CA2561164A1 (en) * 2004-04-01 2005-10-20 Elan Pharmaceuticals, Inc. Steroid sparing agents and their use
CA2579038A1 (en) * 2004-09-02 2006-03-16 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
EP3037544A1 (en) * 2005-10-13 2016-06-29 Human Genome Sciences, Inc. Methods and compositions for use in treatment of systemic lupus erythematosus (sle) patients with autoantibody positive diseases
BRPI0617477A2 (en) * 2005-10-19 2011-07-26 Teva Pharma mixture of crystalline particles of sodium laquinimod, composition, process of crystallization of laquinimod sodium, laquinimod sodium, and process for producing a pharmaceutical composition
DK1951674T3 (en) * 2005-10-26 2012-01-02 Merck Serono Sa Sulfonamide derivatives and their use for modulation of metalloproteinases
US20080108641A1 (en) * 2006-02-08 2008-05-08 Ajami Alfred M Compounds for treating inflammatory disorders, demyelinating disdorders and cancers
US8367629B2 (en) * 2006-02-14 2013-02-05 Noxxon Pharma Ag MCP-1 binding nucleic acids and use thereof
JP2009531304A (en) * 2006-02-28 2009-09-03 エラン ファーマシューティカルズ，インコーポレイテッド Methods for treating inflammatory and autoimmune diseases using alpha-4 inhibitor compounds
JP2009528359A (en) * 2006-02-28 2009-08-06 エラン ファーマシューティカルズ，インコーポレイテッド Methods of treating inflammatory and autoimmune diseases with natalizumab
SG170058A1 (en) * 2006-03-03 2011-04-29 Elan Pharm Inc Methods of treating inflammatory and autoimmune diseases with natalizumab
US9399061B2 (en) * 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
WO2007139887A2 (en) * 2006-05-22 2007-12-06 Cargill, Incorporated Methods for treating bone or joint inflammation
US20080118553A1 (en) * 2006-06-12 2008-05-22 Anton Frenkel Tannate salt form of polypeptide mixtures, their preparation and use
EP2035001B1 (en) * 2006-06-12 2011-11-09 Teva Pharmaceutical Industries Limited Stable laquinimod preparations
US20080090897A1 (en) * 2006-08-11 2008-04-17 The Johns Hopkins University Compositions and methods for neuroprotectin
US8138201B2 (en) * 2007-07-11 2012-03-20 Medicinova, Inc. Treatment of progressive neurodegenerative disease with ibudilast
PL2682120T3 (en) * 2007-12-20 2017-02-28 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
BRPI0913518A2 (en) * 2008-09-03 2016-07-26 Teva Pharma compound, pharmaceutical composition, and method of treating an immune function mediated disorder
MX2011013902A (en) * 2009-06-19 2012-02-23 Teva Pharma Treatment of multiple sclerosis with laquinimod.
ME02414B (en) * 2009-07-30 2016-09-20 Teva Pharma Treatment of crohn's disease with laquinimod
EP3064206B1 (en) * 2009-08-10 2019-03-20 Active Biotech AB Treatment of huntington's disease using laquinimod
PT2542080T (en) * 2010-03-03 2016-11-16 Teva Pharma Treatment of lupus arthritis using laquinimod
SG10201505236YA (en) * 2010-07-09 2015-08-28 Teva Pharma Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
KR20150143499A (en) * 2013-03-14 2015-12-23 테바 파마슈티컬 인더스트리즈 리미티드 Crystals of laquinimod sodium and improved process for the manufacture thereof

Also Published As

Publication number Publication date
MX342001B (en) 2016-09-09
US20130184310A1 (en) 2013-07-18
CO6630086A2 (en) 2013-03-01
CN102781239A (en) 2012-11-14
US20110217295A1 (en) 2011-09-08
AU2011223702B2 (en) 2016-07-14
PE20130496A1 (en) 2013-05-08
JP2013521305A (en) 2013-06-10
US20160213663A1 (en) 2016-07-28
CL2012002422A1 (en) 2012-12-21
BR112012022064A2 (en) 2015-09-08
CA2791711A1 (en) 2011-09-09
EP2542080A4 (en) 2013-07-17
WO2011109536A1 (en) 2011-09-09
US20150086549A1 (en) 2015-03-26
JP2016196473A (en) 2016-11-24
HK1177876A1 (en) 2013-08-30
EA201290859A1 (en) 2013-04-30
MX2012010071A (en) 2012-10-03
EP2542080A1 (en) 2013-01-09
PL2542080T3 (en) 2017-02-28
EP2542080B1 (en) 2016-08-31
KR20130036217A (en) 2013-04-11
ZA201207125B (en) 2014-06-25
NZ602512A (en) 2014-07-25
CN102781239B (en) 2015-01-21
ES2601819T3 (en) 2017-02-16
AU2011223702A1 (en) 2012-10-25
PT2542080T (en) 2016-11-16
SG183515A1 (en) 2012-10-30

Similar Documents

Publication Publication Date Title
HK1177876A1 (en) Treatment of lupus arthritis using laquinimod
IL250357A0 (en) Treatment of lupus nephritis using laquinimod
HK1243417A1 (en) Pyridone and aza-pyridone compounds and methods of use
IL252699A0 (en) Treatment of multiple sclerosis with laquinimod
ZA201304280B (en) Treatment of jak2-mediated conditions
HK1178149A1 (en) Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use -4---
GB201106960D0 (en) Treatment of waste
GB201018147D0 (en) Method of treatment
SG2014014724A (en) METHODS FOR THE TREATMENT OF IL-1ß RELATED CONDITIONS
IL256026B (en) Methods of treatment
GB201003920D0 (en) Method of treatment
HK1249427A1 (en) Arthritis treatment
ZA201103007B (en) Treatment of tantalium-and/or niobium-containing compounds
EP2611884A4 (en) Treatment of hydrocarbon feed
EP2585103A4 (en) Method of treatment
GB201018149D0 (en) Method of treatment
GB201020015D0 (en) Method of treatment
GB201005071D0 (en) Method of treatment
GB201003917D0 (en) Method of treatment
GB201000318D0 (en) Method of treatment
HU1000688D0 (en) Use of trifluoro-phal